Cargando…

Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy

Cytokine-induced killer (CIK) cells are demonstrated to possess potent cytolytic effect against ovarian cancer cells in vitro and in vivo. However, the clinical efficacy of maintenance therapy of CIK cells in patients with epithelial ovarian cancer (EOC) after first-line treatment remains unclear. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yun, Chen, Chang-long, Jiang, Sen-wei, Feng, Yanling, Yuan, Linjing, Chen, Ping, Zhang, Lan, Huang, Shuting, Li, Jundong, Xia, Jian-Chuan, Zheng, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343777/ https://www.ncbi.nlm.nih.gov/pubmed/30713783 http://dx.doi.org/10.1080/2162402X.2018.1528411

Ejemplares similares

Adjuvant Chemotherapy With Sequential Cytokine-Induced Killer (CIK) Cells in Stage IB Non-Small Cell Lung Cancer
por: Li, Da-Peng, et al.
Publicado: (2015)

Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer
por: Liu, Guiyuan, et al.
Publicado: (2022)

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
por: Zhou, Zi-Qi, et al.
Publicado: (2019)

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019)

Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum‐based adjuvant chemotherapy
por: Yamamoto, Makoto, et al.
Publicado: (2016)

CD300LG improves the cytotoxic activity of CIK
por: Wang, Qiuyue, et al.
Publicado: (2017)

Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy
por: Zhao, Ming, et al.
Publicado: (2020)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Case Report: Chemotherapy and Radiotherapy Combined With DC-CIK for Pulmonary and Mediastinal Metastases From Nasopharyngeal Carcinoma
por: Gan, Yi-Xiu, et al.
Publicado: (2022)

Adjuvant chemotherapy after radical cystectomy: Do all patients who need chemotherapy after surgery actually receive it?
por: Croock, Roy, et al.
Publicado: (2023)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur–uracil as postoperative adjuvant chemotherapy
por: Nishikubo, Megumi, et al.
Publicado: (2023)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Lin, Hao, et al.
Publicado: (2021)

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
por: Wang, Mingxing, et al.
Publicado: (2017)

Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020)

Prognostic and Predictive Model for Stage II Colon Cancer Patients With Nonemergent Surgery: Who Should Receive Adjuvant Chemotherapy?
por: Zhang, Chun-Dong, et al.
Publicado: (2016)

Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: A single-center experience
por: Liu, Yu, et al.
Publicado: (2020)

Combination treatment of pembrolizumab with DC-CIK cell therapy for advanced hepatocellular carcinoma: A case report
por: Huang, Shao M., et al.
Publicado: (2023)

Comparative Proteomic Analysis of Lysine Acetylation in Fish CIK Cells Infected with Aquareovirus
por: Guo, Hong, et al.
Publicado: (2017)

The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer – A Retrospective Study
por: Seebacher, Veronika, et al.
Publicado: (2017)

Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible
por: Ma, Xiaoting, et al.
Publicado: (2023)

Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
por: Chen, Wei-Chun, et al.
Publicado: (2022)

Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
por: Chen, Po-Huang, et al.
Publicado: (2022)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Is adjuvant chemotherapy necessary for young women with early-stage epithelial ovarian cancer who have undergone fertility-sparing surgery?: a multicenter retrospective analysis
por: Ikeda, Yoshiki, et al.
Publicado: (2022)

CIK细胞及其在肺癌治疗中的研究进展
Publicado: (2011)

Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab
por: Shinano, Hiromi, et al.
Publicado: (2020)

Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
por: Jia, Xiongjie, et al.
Publicado: (2023)

Implication of KDR Polymorphism rs2071559 on Therapeutic Outcomes and Safety of Postoperative Patients with Gastric Cancer Who Received S-1-Based Adjuvant Chemotherapy: A Real-World Exploratory Study
por: Meng, Lei, et al.
Publicado: (2023)

Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer
por: Matsuo, Koji, et al.
Publicado: (2019)

miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway
por: Xu, Manman, et al.
Publicado: (2018)

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
por: Zhang, Yajing, et al.
Publicado: (2013)

Adjuvant chemotherapy for stage II colon cancer: who really needs it
por: Yang, Yan, et al.
Publicado: (2018)

Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial
por: Ito, Seiji, et al.
Publicado: (2018)

Pneumocystis pneumonia during Postoperative Adjuvant Chemotherapy for Breast Cancer
por: Shinohara, Tsuyoshi, et al.
Publicado: (2013)

DC‐CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1‐ASK1‐AIP1 pathway to kill autologous ovarian cancer stem cells
por: Qin, Wenxing, et al.
Publicado: (2018)

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

The destiny of the resistance/susceptibility against GCRV is controlled by epigenetic mechanisms in CIK cells
por: Shang, Xueying, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_91s9i1scn4dejtek53iujpbitl